This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from AstraZeneca. The activity is jointly provided by USF Health and touchIME. touchIME is an EBACĀ® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download Module 1 Slides
    Download Module 1, Clinical Summary
    Download Module 1 Slides
    Download Module 1 Slides
    Download Module 1 Slides
    Download Module 1 Slides
    Download Module 1 Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Helena Yu

    Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dr Helena Yu is an associate attending and the research director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY, USA. read more

    In addition to her role as a practising medical oncologist, Dr Yu is a clinical and translational researcher with a focus on improving the survival of patients with EGFR-mutant lung cancers. She oversees the research programme for EGFR-mutant lung cancers at MSK, which includes developing effective new therapies for lung cancer, identifying biomarkers for targeted treatments, lineage plasticity and adaptive mutagenesis as pathways of resistance to targeted therapy, and establishing risk-adaptive treatment strategies that tailor treatment to patients based on risk. Dr Yu has established several mechanisms of resistance to first- and third-generation EGFR tyrosine kinase inhibitors and reported on the prognostic significance of concurrent alterations in EGFR-mutant lung cancer seen on next-generation sequencing.Ā 

    Dr Yu has been the principal investigator of 30 clinical trials, including 10 investigator-initiated trials, focused on EGFR-mutant lung cancer.

    Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
    Dr Antonio Passaro

    European Institute of Oncology, Milan, Italy

    Dr Antonio Passaro is a medical oncologist and currently holds the position of senior staff physician at the Division of Thoracic Oncology, European Institute of Oncology in Milan, Italy. read more

    Dr Passaro is a global authority and leader in lung cancer research and clinical practice. His main areas of research and clinical interest are predictive biomarkers, in particular EGFR and related targeted and immunotherapy agents, from discovery to validation in the clinical setting. He is also highly involved in the use of targeted agents in non-metastatic settings, either alone, or in a multimodality approach, for early or locally-advanced disease.Ā 

    Dr Passaro is involved in a portfolio of many clinical trials, both industry-funded and academic, investigating a range of novel lung cancer therapies. He has published more than 120 articles in peer-reviewed journals. He also serves as a member of several national and international scientific committees. Notably, he has authored guidelines for ESMO (European Medical Society for Medical Oncology) and AIOM (Italian Association of Medical Oncology), guiding the management and treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

    Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
    Back to Faculty
    touchRESPIRATORY touchRESPIRATORY
    Play ArrowPlay Video

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What are you most interested in learning about from ongoing clinical trials?

    Submit your answer to see the results

    Outcomes in patients with brain metastases
       
    Outcomes in high-risk patients
       
    Role of biomarkers in personalizing treatment
       
    Overall survival rates for combination approaches
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which of the following treatments is most likely to change your clinical practice?

    Submit your answer to see the results

    Osimertinib + chemotherapy
       
    Amivantamab + lazertnib
       
    Amivantamab + chemotherapy
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which is the most important area for research in late-stage EGFR-mutant NSCLC?

    Submit your answer to see the results

    Management of CNS metastases/leptomeningeal disease
       
    Biomarkers to monitor/predict treatment response
       
    Identifying patients for risk-adaptive treatment strategies
       
    Understanding specific resistance mutations
       
    Play ArrowPlay Video

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What are you most interested in learning about from ongoing clinical trials?

    Submit your answer to see the results

    Outcomes in patients with brain metastases
       
    Outcomes in high-risk patients
       
    Role of biomarkers in personalizing treatment
       
    Overall survival rates for combination approaches
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which of the following treatments is most likely to change your clinical practice?

    Submit your answer to see the results

    Osimertinib + chemotherapy
       
    Amivantamab + lazertnib
       
    Amivantamab + chemotherapy
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which is the most important area for research in late-stage EGFR-mutant NSCLC?

    Submit your answer to see the results

    Management of CNS metastases/leptomeningeal disease
       
    Biomarkers to monitor/predict treatment response
       
    Identifying patients for risk-adaptive treatment strategies
       
    Understanding specific resistance mutations
       
    Play ArrowPlay Video

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What are you most interested in learning about from ongoing clinical trials?

    Submit your answer to see the results

    Outcomes in patients with brain metastases
       
    Outcomes in high-risk patients
       
    Role of biomarkers in personalizing treatment
       
    Overall survival rates for combination approaches
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which of the following treatments is most likely to change your clinical practice?

    Submit your answer to see the results

    Osimertinib + chemotherapy
       
    Amivantamab + lazertnib
       
    Amivantamab + chemotherapy
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which is the most important area for research in late-stage EGFR-mutant NSCLC?

    Submit your answer to see the results

    Management of CNS metastases/leptomeningeal disease
       
    Biomarkers to monitor/predict treatment response
       
    Identifying patients for risk-adaptive treatment strategies
       
    Understanding specific resistance mutations
       

    touchCLINICAL PERSPECTIVES
    A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close

    Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

    Claim Credit

    Part 1 ćƒ¼ EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC

    Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.

    After watching this activity, participants should be better able to:

    1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

    Part 2 ćƒ¼EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies

    Dr Antonio Passaro, an oncologist specializing in lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-mutant metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings.

    After watching this activity, participants should be better able to:

    1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

    Part 3 ćƒ¼EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice

    Dr Helena Yu provides an overview of the current treatment options for EGFR-mutant metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and at the point of disease progression, as well as how ongoing research and the advent of new therapies and combination strategies might impact future treatment approaches.

    After watching this activity, participants should be better able to:

    1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
    2. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.

    Modules

    Time: 08:53

    Module 1 ā€“ Part 1:
    EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC

    Time: 09:37

    Module 1 ā€“ Part 2:
    EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies

    Time: 13:22

    Module 1 ā€“ Part 3:
    EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice

    Coming Soon

    Module 2 - Part 1:
    Advances in the treatment landscape for EGFR-wildtype NSCLC

    Coming Soon

    Module 2 - Part 2:
    Insights from the latest data and strategies for improvement

    Coming Soon

    Module 2 - Part 3:
    Practical insights and implications for NSCLC practice

    Coming Soon

    Module 3 - Part 1:
    Novel strategies, care pathways and side effect management

    Coming Soon

    Module 3 - Part 2:
    Implications of novel treatments on the shifting biomarker landscape

    Coming Soon

    Module 3 - Part 3:
    Optimizing outcomes in late-stage NSCLC: Key learnings

    You may also be interested in...

    touchPANEL DISCUSSION

    Expanding HER2 horizons: Implications for NSCLC and beyond

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchEXPERT OPINIONS

    Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer

    GO TO HUB

    CONFERENCE HUB

    Rolof Gijtenbeek, ERS 2021: The NVALT 17 Study

    GO TO HUB

    JOURNALS

    The Use of Sweetened and Flavored Electronic Cigarettes Among Young Peopleā€”a Growing Concern

    GO TO ARTICLE

    JOURNALS

    Endobronchial Involvement in Sarcoidosis

    GO TO ARTICLE

    Topics covered in this activity

    Lung Cancer / Thoracic Oncology
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 1000+ topical and insightful peer-reviewed journal articles
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from AstraZeneca.
    The activity is jointly provided by USF Health and touchIME.
    touchIME is an EBACĀ® accredited provider.

    USF Health

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patientā€™s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individualā€™s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBACĀ®

    touchIME is an EBACĀ® accredited provider since 2023.

    In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 26 September 2024. Date credits expire: 26 September 2025.

    Claim Credit
    touchCLINICAL PERSPECTIVES
    Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
    0.5 CE/CME credit
    Question 1/2
    Which of the following statements best reflects the recent outcomes of the FLAURA2 trial evaluating osimertinib Ā± Pt-ChT in EGFR-mutant NSCLC?

    AE, adverse event; CNS, central nervous system; EGFR, epidermal growth factor receptor; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

    The phase III FLAURA2 study, investigating osimertinib Ā± Pt-ChT in EGFR-mutant advanced NSCLC, demonstrated a median PFS of 25.5 months in the overall population receiving the combination vs 16.7 months in patients receiving osimertinib alone (HR 0.62; 95% CI 0.49ā€“0.79; p<0.001). A PFS benefit in favour of the combination group was observed across prespecified subgroup populations, including patients with an exon 19 deletion, exon 21 (L858R) mutation, with CNS metastases and without CNS metastases. The rate of grade ā‰„3 AEs was higher in the combination group than the osimertinib monotherapy group (64 vs 27%).

    Abbreviations
    AE, adverse event; CI, confidence interval; CNS, central nervous system; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

    Reference
    Planchard D, et al. N Engl J Med. 2023;389:1935ā€“48.

    Question 2/2
    Your patient is a 54-year-old woman with a stage IV EGFR-mutant NSCLC harbouring an exon 19 deletion mutation. Following administration of osimertinib QD for a period of 18 months, she has evidence of disease progression with the development of brain metastases. Which of the following agents might you select based on recent clinical trial data (and providing all agents are available) that could be added to the standard of care chemotherapy in the second-line setting to improve your patientā€™s outcomes?

    EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; QD, once daily.

    The phase III MARIPOSA-2 evaluated intravenous amivantamab + chemotherapy with or without lazertinib vs chemotherapy alone in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib. PFS was significantly longer with amivantamab + chemotherapy vs chemotherapy alone in all randomized patients (HR 0.48; 95% CI 0.36ā€“0.64; p<0.001) and in patients with a history of brain metastasis (HR 0.52; 95% CI 0.35ā€“0.78).1Ā Ā 

    The PFS was also significantly longer in the amivantamab + lazertinib + chemotherapy arm vs chemotherapy alone (HR 0.44, 95% CI 0.35-0.56, p< 0.001). However, AEs of grade 3 or higher, mainly due to haematologic toxicities, were higher in the amivantamab + lazertinib + chemotherapy arm vs both amivantamab + chemotherapy and chemotherapy alone, which led to a regimen change during the trial for the triplet therapy arm.1 Longer follow-up is required for this modified regimen.

    The antibodyā€“drug conjugate patritumab deruxtecan has been evaluated as a third- or later-line monotherapy agent only in patients who had previously been treated with osimertinib and one or more prior lines of chemotherapy in the HERTHENA-Lung01 study.2Ā 

    Abbreviations

    AE, adverse event; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival.Ā 

    References

    1. Passaro A, et al. Ann Oncol. 2024;35:77ā€“90.
    2. Yu HA, et al. J Clin Oncol. 2023;41:5363ā€“75.
    Back to Activity

    You may also be interested in...

    touchFOCUS

    Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Daniel Steinfort, WCBIP 2022: Findings from the SEISMIC Study

    GO TO HUB

    touchMDT

    Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Gerard A. Silvestri, CHEST 2022: Managing Complications in the Treatment of Lung Cancer (Part 1)

    GO TO HUB

    JOURNALS

    The Use of Sweetened and Flavored Electronic Cigarettes Among Young Peopleā€”a Growing Concern

    GO TO ARTICLE

    JOURNALS

    Sarcomatoid Carcinoma of the Lung Mimicking a Thromboembolic Disease

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from AstraZeneca.
    The activity is jointly provided by USF Health and touchIME.
    touchIME is an EBACĀ® accredited provider.

    USF Health

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patientā€™s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individualā€™s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBACĀ®

    touchIME is an EBACĀ® accredited provider since 2023.

    In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 26 September 2024. Date credits expire: 26 September 2025.

    Faculty
    Downloads
    Featured
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72